AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.94
+0.24 (+1.75%)
As of 2:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.70
Open13.83
Bid13.96 x 1800
Ask13.96 x 800
Day's Range13.42 - 14.07
52 Week Range10.76 - 33.95
Volume995,493
Avg. Volume3,226,014
Market Cap1.746B
Beta1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est22.54
Trade prices are not sourced from all markets
  • Reuters6 days ago

    Fresenius CEO defends cancelled Akorn deal

    FRANKFURT/BERLIN, May 18 (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Sturm served as chief financial officer before taking over as CEO in 2016 and has helped build the German company into a globally diversified healthcare group through a series of multi-billion dollar deals.

  • ACCESSWIRE13 days ago

    Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

  • Investopedia16 days ago

    Top 3 Companies Owned by Valeant

    Part of the healthcare sector, Valeant Pharmaceuticals International Inc. (NYSE: VRX), is a specialty pharmaceutical company, operating in multiple countries. Valeant manufactures and markets a large bouquet of pharmaceutical products. Primary areas of focus include eye health, dermatology, neurology and generically branded medications, including over-the-counter (OTC) drugs.

  • ACCESSWIRE17 days ago

    DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") ...

  • ACCESSWIRE17 days ago

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm

    LOS ANGELES, CA / ACCESSWIRE / May 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 1, 2017, and February 26, 2018, are encouraged to contact the firm before May 7, 2018, the lead plaintiff deadline.

  • ACCESSWIRE17 days ago

    FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities during the period between March 1, 2017 through February 26, 2018, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/akrx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

  • ACCESSWIRE20 days ago

    DEADLINE MONDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) who purchased shares between ...

  • Analyzing the Cash Flows and Valuation Metrics of Akorn
    Market Realist20 days ago

    Analyzing the Cash Flows and Valuation Metrics of Akorn

    Should You Keep an Eye on Akorn in 2018? Akorn (AKRX) used up $31.6 million in operating activities in 1Q18. In 1Q18, Akorn used $22.3 million in investing activities to acquire property, plants, and equipment.

  • Exploring Akorn’s Financial Performance
    Market Realist20 days ago

    Exploring Akorn’s Financial Performance

    Should You Keep an Eye on Akorn in 2018? In 1Q18, Akorn (AKRX) generated total revenue of $184 million compared to $253.4 million in 1Q17. Akorn’s ephedrine sulfate injection and lidocaine ointment saw sales erosion in 1Q18.

  • Analyzing the Performances of Akorn’s Business Segments
    Market Realist20 days ago

    Analyzing the Performances of Akorn’s Business Segments

    Should You Keep an Eye on Akorn in 2018? The Prescription Pharmaceuticals segment primarily consists of generic and branded prescription products. The Consumer Health segment consists of animal health and OTC (over-the-counter) products, both branded and private label.

  • ACCESSWIRE20 days ago

    Pawar Law: Important May 7, 2018 Lead Plaintiff Deadline in Akorn, Inc. Class Action- AKRX

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Pawar Law Group reminds shareholders who purchased shares of Akorn, Inc. (NASDAQ: AKRX) from March 1, 2017 through February 26, 2018, both dates inclusive ("Class ...

  • ACCESSWIRE20 days ago

    DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities during the period between March 1, 2017 through February 26, 2018, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

  • Benzinga20 days ago

    Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...

  • ACCESSWIRE21 days ago

    MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm

    LOS ANGELES, CA / ACCESSWIRE / May 3, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 1, 2017, and February 26, 2018, are encouraged to contact the firm before May 7, 2018, the lead plaintiff deadline.

  • ACCESSWIRE21 days ago

    AKRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Illinois on behalf ...

  • Fresenius sees Akorn lawsuit dragging on into 2019
    Reuters21 days ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Reuters21 days ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Business Wire22 days ago

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX

    Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (“Akorn” or the “Company”) (AKRX) and certain of its officers. The class action, filed in United States District Court, for the District of Illinois, Eastern Division, is on behalf of a class consisting of investors who purchased or otherwise acquired Akorn’s securities between March 1, 2017 through February 26, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • Reuters22 days ago

    Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

    WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn slid nearly 15 percent on Wednesday to end at $12.55 per share.

  • Here's Why Akorn Inc Fell as Much as 16.4% Today
    Motley Fool22 days ago

    Here's Why Akorn Inc Fell as Much as 16.4% Today

    Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.

  • ACCESSWIRE22 days ago

    DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm

    LOS ANGELES, CA / ACCESSWIRE / May 2, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • Reuters22 days ago

    Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

    WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion (3.5 billion pounds), according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn fell more than 8 percent in early trading Nasdaq on Wednesday to $13.57 per share.

  • ACCESSWIRE22 days ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") ...